Sodium aescinate

CAT:
804-HY-N1404-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Sodium aescinate - image 1

Sodium aescinate

  • UNSPSC Description:

    Sodium aescinate is a triterpene saponin derived from Aesculus hippocastanum seeds, with anti-inflammatory and antioxidant activities[1]. Sodium aescinate inhibits hepatocellular carcinoma growth by targeting CARMA3/NF-κB pathway[2].
  • Target Antigen:

    NF-κB
  • Type:

    Natural Products
  • Related Pathways:

    NF-κB
  • Applications:

    COVID-19-immunoregulation
  • Field of Research:

    Cancer; Inflammation/Immunology
  • Assay Protocol:

    https://www.medchemexpress.com/sodium-aescinate.html
  • Purity:

    99.26
  • Solubility:

    DMSO : 100 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)
  • Smiles:

    CC(C(OC[C@@]12[C@H]3C[C@]4(C)C([C@]1([H])CC(C)(C)[C@H](O3)[C@@H]2O)=CC[C@@]5([H])[C@@]4(C)CC[C@]6([H])[C@]5(C)CC[C@H](O[C@@H]7O[C@H](C(O[Na])=O)[C@@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9OC[C@@H](O)[C@H](O)[C@H]9O)[C@]6(CO)C)=O)C(OC(C)=O)C
  • Molecular Weight:

    1123.21
  • References & Citations:

    [1]Zhang Z, et al. The Efficacy of Sodium Aescinate on Cutaneous Wound Healing in Diabetic Rats. Inflammation. 2015 Oct;38(5):1942-8.|[2]Hou H, et al. CARMA3/NF-κB signaling contributes to tumorigenesis of hepatocellular carcinoma and is inhibited by sodium aescinate. World J Gastroenterol. 2019 Sep 28;25(36):5483-5493.|[3]Qi SM, et al. Effect of sodium aescinate in inducing human breast cancer MCF-7 cells apoptosis by inhibiting AKT, ERK and upstream signal SRC activity. Zhongguo Zhong Yao Za Zhi. 2015 Aug;40(16):3267-72.|[4]Chen L, et al. Effect of sodium aescinate treatment on PCOS rat model with insulin resistance. Bratisl Lek Listy. 2017;118(4):223-227.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    4°C (Powder, sealed storage, away from moisture and light)
  • Clinical Information:

    Launched
  • CAS Number:

    20977-05-3